Hyloris’ dispute with AltaThera over the cardiovascular drug Sotalol IV has reached another milestone with a final verdict from an arbitration panel, which cleared Hyloris of financial liabilities while also denying its own claims.
The dispute between Hyloris Pharmaceuticals and AltaThera Pharmaceuticals over claims linked to the cardiovascular drug Sotalol IV has seen another key development after the issuing of a final opinion from an arbitration panel between the two players.
Hyloris originally partnered with AltaThera for the US commercialization of its compound Sotalol IV, which is an intravenous formulation of the otherwise oral dug
The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.
Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.
Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.
